Each 10 ml vial contains Dacarbazine IP 100 mg
Each 20 ml vial contains Dacarbazine IP 200 mg
Each 50 ml vial contains Dacarbazine IP 500 mg
Without a Prescription
Dacarbazine is prescribed in the treatment of metastatic malignant melanoma, Hodgkin’ disease as a secondary-line therapy when used in combination with other effective agents, neuroblastoma, soft-tissue sarcoma including leomyosarcoma.
The recommended dosage of Dacarbazine is 2 to 4.5mg/kg/day for 10 days.
Treatment may be repeated at 4-week intervals. An alternate recommended dosage is 250mg/square meter body surface/day I.V. for 5 days.
Treatment may be repeated every 3 weeks.
The recommended dosage of Dacarbazine in the treatment of Hodgkin’ disease is 150mg/ square meter body surface/day for 5 days, in combination with other effective drugs.
Treatment may be repeated every 4 weeks.
An alternative recommended dosage is 375mg/square meter body surface on day 1, in combination with other effective drugs, to be repeated every 15 days.
Combination with other antineoplastic agents.
Dosage of Dacarbazine must be based on the clinical hematologic response and tolerance of the patient in order to obtain optimal therapeutic results.
Dacarbazine is contraindicated in patients who have demonstrated a hypersensitivity to it in the past.
- Vial of 10 ml;
- Vial of 20 ml;
- Vial of 50 ml;